{"entity":{"id":"nct07114861","kind":"trial","name":"The KN510713 Study in Combination With mFOLFIRINOX","aka":[],"tldr":"A phase 1/2 trial of Study drug: KN510 120mg/day + KN713 90mg/day, Combination Chemotherapy: mFOLFIRINOX in pancreatic ductal adenocarcinoma, run by New Cancer Cure-Bio Co.,Ltd., now recruiting.","summary":"The KN510713 Study in Combination With mFOLFIRINOX is a phase 1/2 interventional study registered as NCT07114861 by New Cancer Cure-Bio Co.,Ltd., with 30 participants planned, started 2025-12-16 and due to reach its primary completion in 2028-09-22. Interventions recorded: Study drug: KN510 120mg/day + KN713 90mg/day, Combination Chemotherapy: mFOLFIRINOX and Study drug: KN510 120mg/day + KN713 120mg/day, Combination Chemotherapy: mFOLFIRINOX.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07114861","url":"https://clinicaltrials.gov/study/NCT07114861"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07114861","phase":"1/2","setting":"An Open-label, Dose-finding and Dose-expansion, Phase I/IIa Clinical Trial to Evaluate the Safety and Efficacy of KN510713 in Combination With mFOLFIRINOX in Patients With Locally Advanced or Metastatic Pancreatic Cancer","sponsor":"New Cancer Cure-Bio Co.,Ltd.","enrolled":30,"outcomes":[]},"route":"/trials/nct07114861/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}]}}